| ABSTRACT Objective::To compare the clinical effects of 4 kinds of treatment programs for postmenopausal women on primary hyperlipidemia, and to analyze their cost-effectiveness and evaluate their safety with the medical economics method. Methods:The randomized controlled clinical study was used. 104 postmenopausal women with primary hyperlipidemia were divided into 4 group: Group A (atorvastatin calcium tablets), Group B(rosuvastatin calcium tablets), Group C (fenofibrate sustained release capsules) and Group D(fenofibrate sustained release capsules combined with simvastatin dispersible tablets), respectively. The patients were treated for 2 months. Such indicators as TC, TG, LDL-C HDL-C were measured before and after the treatment. The cost-effectiveness ratio and safety evaluation were analyzed. Results:The cost of Group A, B, C and D was 265.8, 246.6, 235.2 and 364.5 RMB, respectively. After the analysis, the cost effectiveness ratio of Group C was the lowest in their TC, TG and HDL-C indicators and that of Group B was the lowest in the LDL-C indicator. Conclusion:When TC, TG and HDL C for postmenopausal women were high, they could select Group C program while those who had their high LDL-C could select Group B program. |
